Kintara Therapeutics (KTRA) Receives a Hold from Dawson James
November 20 2022 - 08:25AM
TipRanks
In a report released on November 18, Jason Kolbert from Dawson
James maintained a Hold rating on Kintara Therapeutics (KTRA -
Research Report). The company's shares closed last Friday at
$4.01.According to TipRanks, Kolbert is an analyst with an average
return of -5.1% and a 33.42% success rate. Kolbert covers the
Healthcare sector, focusing on stocks such as BioCardia, Can-Fite
BioPharma, and Daré Bioscience.Kintara Therapeutics has an analyst
consensus of Hold.See the top stocks recommended by analysts
>>The company has a one-year high of $42.08 and a one-year
low of $3.67. Currently, Kintara Therapeutics has an average volume
of 56.84K.
https://www.tipranks.com/news/blurbs/kintara-therapeutics-ktra-receives-a-hold-from-dawson-james?utm_source=advfn.com&utm_medium=referral
Kintara Therapeutics (NASDAQ:KTRA)
Historical Stock Chart
From Feb 2023 to Mar 2023
Kintara Therapeutics (NASDAQ:KTRA)
Historical Stock Chart
From Mar 2022 to Mar 2023
